Patients with idiopathic pulmonary fibrosis (IPF) in Canada face challenges in equal access to quality healthcare services at the national level, with drastic differences between provinces, according to the findings of a new report from the Canadian Pulmonary Fibrosis Foundation (CPFF) and Hoffmann-La Roche. The report, titled…
Delays in diagnosis and difficulty getting timely access to appropriate specialist care and treatment were highlighted as major gaps in care in a recent survey of people with pulmonary fibrosis (PF) and their healthcare providers. The survey results were discussed in the journal ERJ Open Research in a study,…
UCLA Health has launched a $20-million fundraising initiative to support the creation of a new research and treatment center for advanced lung diseases, including idiopathic pulmonary fibrosis (IPF), at the David Geffen School of Medicine at UCLA. The Lung Health Research Accelerator Fund…
Roche has acquired Promedior, a biotechnology company, and its full portfolio of molecules to possibly treat fibrotic diseases. The portfolio includes PRM-151, a lead therapy candidate for  idiopathic pulmonary fibrosis (IPF) advancing in clinical testing. PRM-151 is a synthetic engineered version of pentraxin-2, a protein that is able to…
A model of the human lung constructed with the help of tissue samples from 10 idiopathic pulmonary fibrosis (IPF) patients details changes in gene activity that precede evident fibrosis, a study reports. This model is a sort of genetic roadmap to IPF progression that may help researchers find treatments for…
Chronic viral infections caused by the Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus 7 (HHV7), and herpesvirus 8 (HHV8) increase the risk of idiopathic pulmonary fibrosis (IPF), but not of acute flares that mark disease worsening, according to data from a meta-analysis study. The study,…
A metabolic process called the mevalonate pathway may be a promising therapeutic target to fight idiopathic pulmonary fibrosis (IPF), according to an early research study using mouse models and lung fluid collected from IPF patients. Researchers also suggest that lung injury may not be as key…
Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare…
Indalo Therapeutics’ lead investigational anti-fibrotic candidate, IDL-2965, is safe and shows favorable pharmacokinetics (absorption, distribution, and elimination in the body) in healthy people, according to interim results of a Phase 1/2a clinical trial. The results were presented at the Pulmonary Fibrosis Foundation (PFF) Summit, held Nov. 7–9 in…
Exposure to dust in the workplace for 10 years or longer seems to have no detrimental effect on the response of patients with idiopathic pulmonary fibrosis (IPF) to anti-fibrotic treatment with Esbriet (pirfenidone) or Ofev (nintedanib), a study has found. The study “Antifibrotic treatment response and…
Get regular updates to your inbox.
